Skip to main content

Table 3 Relative quantification of cytokines' mRNA and their protein concentration

From: Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma

 

SCT mean (SD) [% > DR]

DEX mean (SD) [% > DR]

SCT T2 versus T1 difference

DEX versus SCT for T2 and T1 difference

 

T1

T2

T1

T2

Effecta [95% CI]

P value (adjusted)

Effectb [95% CI]

P value (adjusted)

IL-1β*

22.510 (17.260)

24.078 (34.070)

27.651 (30.293)

11.089 (16.941)

0.608 [0.281; 1.315]

0.19 (0.4)

0.472 [0.171; 1.307]

0.14 (0.3)

IL-4*

0.140 (0.106)

0.190 (0.385)

0.116 (0.122)

0.182 (0.359)

0.812 [0.329; 2.003]

0.6 (0.7)

0.796 [0.252; 2.510]

0.7 (0.8)

IL-8*

7470.490 (5017.252)

8013.460 (11,453.562)

10,222.300 (13,818.670)

5742.500 (4475.492)

0.607 [0.296; 1.245]

0.2 (0.4)

1.137 [0.445; 2.905]

0.8 (0.8)

IL-17*

0.019 (0.014)

0.009 (0.010)

0.020 (0.021)

0.005 (0.008)

0.409 [0.201; 0.831]

0.02 (0.05)

0.432 [0.167; 1.120]

0.08 (0.2)

TNFα*

146.908 (140.452)

112.709 (119.865)

113.907 (67.441)

78.013 (48.822)

0.780 [0.487; 1.250]

0.3 (0.4)

0.803 [0.442; 1.458]

0.4 (0.7)

INFy*

2.831 (3.534)

1.610 (1.330)

2.113 (2.654)

1.551 (1.587)

0.665 [0.342; 1.290]

0.2 (0.4)

0.782 [0.330; 1.850]

0.5 (0.7)

eIL-1β*

370.062 (293.004) [90]

279.188 (156.496) [90]

217.321 (84.624) [80]

203.012 (84.247) [60]

0.699 [0.586; 0.833]

 < 0.001 (< 0.001)

0.828 [0.678; 1.011]

0.06 (0.2)

eIL-4*

340.817 (291.316) [100]

257.304 (165.533) [100]

198.584 (97.086) [90]

203.012 (84.247) [60]

0.555 [0.422; 0.731]

 < 0.001 (< 0.001)

0.676 [0.482; 0.949]

0.02 (0.1)

eTNFα*

1102.100 (878.340) [100]

740.418 (759.764) [100]

609.070 (606.676) [100]

473.075 (378.766) [100]

0.553 [0.376; 0.812]

0.005 (0.02)

1.765 [1.033; 3.014]

0.04 (0.1)

  1. Significant values are in bold
  2. e ELISA determined concentration of cytokine, IL Interleukine, SCT Stem cell treatment, DEX Dexamethasone treatment, DR Detection range for ELISA assays, % > DR proportion of variables above DR, T1 Beginning of treatment, T2 End of treatment
  3. *Logarithmic transformation (descriptive values are on the original scale)
  4. aYT2-YT1 (non-transformed outcome) or YT2/YT1 (logarithmic transformation) for SCT as estimated with linear mixed effects model or Tobit regression
  5. b(YT2-YT1)DEX-(YT2-YT1)SCT (non-transformed outcome) or (YT2/YT1)DEX/(YT2/YT1)SCT (logarithmic transformation) as estimated with linear mixed effects model or Tobit random effects model. Additional data are available in graphical form in the Additional file 3: Figure S3